Apellis Pharmaceuticals, Inc. (APLS) reported $268.3 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 60.9%. EPS of $0.15 for the same period compares to -$0.74 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $200.75 million, representing a surprise of +33.65%. The company delivered an EPS surprise of +139.3%, with the consensus EPS estimate being -$0.38.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Apellis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Product Revenue- EMPAVELI: $41.29 million versus $38.09 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +109.3% change.
- Revenue- Licensing and other revenue: $76.29 million versus $18.14 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +351.5% change.
- Revenue- Product revenue, net: $192.01 million compared to the $180.99 million average estimate based on eight analysts. The reported number represents a change of +28.1% year over year.
- Product Revenue- SYFOVRE: $150.72 million compared to the $142.91 million average estimate based on eight analysts. The reported number represents a change of +15.8% year over year.
View all Key Company Metrics for Apellis Pharmaceuticals here>>>
Shares of Apellis Pharmaceuticals have returned +1.1% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
